trial · primary record
Belzutifan
Renal Cell Carcinoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2026-12-22 |
| Primary endpoint | Number of Participants Who Experience at Least One Dose-limiting Toxicity (DLT) |
| Registry ID | NCT05468697 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:42.556Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05468697
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.